Mein Warenkorb

Mouse IgG

Mouse IgG Produktliste

  • Attribut

    Beads (1)Antibody (1)

  • Produktbibliothek

    Online (2)

  • Spezies

    Rabbit (2)

  • Etikett

    - (2)

  • Marker

    - (1)Acridinium ester Labeled (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
AMG-S163
Rabbit
HEK293
Anti-Mouse IgG-Acridinium ester (MALS verified) In den Warenkorb legen
MPC-A003
Rabbit
-
Anti-Mouse IgG-coupled Magnetic Beads (recommended for MPCLIA) In den Warenkorb legen
Gesamtmenge2
  • 1

Mouse IgG Molekülhintergrund

Chemiluminescence immunoassay (CLIA) is a much more effective measurement with the advantages of high sensitivity, uniformity and broad dynamic range. However, in traditional chemiluminescent immunoassay (CLIA),microplate was applied to immobilize antigen or antibody by physical absorption, which holds a negative effect on the perfor-mance of assay because of the low specific surface area of micro-plate. The use of micromagnetic particles (MMPs) have proven to be a support for addressing the shortage of traditional CLIA mentioned above The chemiluminescent immunoassay is a technique used for disease diagnosis, drug development, chemical reaction monitoring, and many other applications. The MMPs-based chemiluminescence immunoassays could improve the surface area for immobilization, capture efficiency and accuracy of the assay, thus obtaining higher sensitivity and shorter analysis time.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
BelapectinGR-MD-02Phase 3 ClinicalGalectin Therapeutics IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
OlitigaltinGB-0139; TD-139Phase 2 ClinicalThe University Of Edinburgh, Lund University FoundationIdiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19)
Details
Galactomannan CGM-CT-01Phase 2 ClinicalGalectin Therapeutics IncHead and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma
Details
SelvigaltinGB-1211; GB1211Phase 2 ClinicalGalecto IncSquamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung
Details
ProLectin-MPhase 2 ClinicalBioXyTran IncCytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human
Details
Gal-400Gal-400Phase 1 ClinicalGalecto IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
OcriplasminA-01016; THR-409ApprovedThrombogenicsJetrea, JejetreaUnited StatesVitreomacular AdhesionThrombogenics Inc2012-10-17Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion
Details
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns